drugset / Trial / NCT01020123

Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients

NCT01020123

Phase 2 Completed 530 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in TD2M Patients

Timeline

Start
2009-10
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1656 Small molecule
Comparator Glipizide Small molecule